In a lab environment, BPC-157 has been studied for its potential in a variety of areas: Support the integrity of the gastrointestinal mucosa Enhance wound healing in skin, tendons, ligaments, and muscles Modulate inflammatory pathways and oxidative stress Interact with the brain-gut axis, a network that connects the nervous system and digestive system As a side note, though no less important, BPC-157 is considered an unapproved new drug and isnt FDA-approved for any human treatment
Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics
Glutathione S-transferases promote proinflammatory astrocyte-microglia communication during brain inflammation
This dose is then usually increased every 30 days until you reach the level that best controls your blood sugar
The FDA continues to explain GLP-1 drugs should not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Today, experts agree that there is no real risk of thyroid cancer associated with GLP-1 drugs
THRIVE myGLP is more than just a product, its a movement
